Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Iambic Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Iambic Therapeutics

Iambic Therapeutics

Series B

Iambic Therapeutics: Pioneering AI-driven drug discovery with a fast, diverse, and high-quality therapeutics pipeline.

HQ
San Diego, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize drug discovery, Iambic Therapeutics leverages advanced machine learning to expedite the development of high-quality therapeutics. The company combines the expertise of leading AI specialists and seasoned drug developers to create a robust platform capable of addressing various target classes and mechanisms of action. Their AI-driven software accelerates research and development, aiming to bring differentiated therapeutics to the clinic faster than traditional methods.

Iambic Therapeutics boasts a team of notable experts in artificial intelligence and pharmaceutical research, contributing to its innovative edge. The company has garnered attention for its ability to deliver clinically validated therapeutics with unprecedented speed. By integrating physics-based AI algorithms into their high-throughput experimental platform, Iambic has significantly impacted the drug discovery process, offering new molecular designs and biological insights on a weekly basis.

Iambic Therapeutics - Similar Companies

Seismic Therapeutic logo

Seismic Therapeutic

Athos Therapeutics logo

Athos Therapeutics

athostx.com

Pathos AI logo

Pathos AI

pathos.com

DeepCure logo

DeepCure

deepcure.ai

Ensem Therapeutics logo

Ensem Therapeutics

ensemtx.com

Nobias Therapeutics logo

Nobias Therapeutics

nobiastx.com

Terray Therapeutics logo

Terray Therapeutics

terraytx.com

TandemAI logo

TandemAI

tandemai.com

Nimble Therapeutics logo

Nimble Therapeutics

Model Medicines logo

Model Medicines

modelmedicines.com

Metis Therapeutics logo

Metis Therapeutics

metistx.com

Cognaisent logo

Cognaisent

cognaisent.com

Superluminal Medicines logo

Superluminal Medicines

superluminalrx.com

Proxima logo

Proxima

proximabio.com

Kimia Therapeutics logo

Kimia Therapeutics

kimiatx.com

Iambic Therapeutics - Quick Facts

Who are Iambic Therapeutics' competitors?

Companies similar to Iambic Therapeutics include Seismic Therapeutic, Athos Therapeutics, Pathos AI and DeepCure.

When was Iambic Therapeutics founded?

Iambic Therapeutics was founded in 2019.

Where is Iambic Therapeutics' headquarters located?

Iambic Therapeutics' headquarters is located in San Diego, CA, US.

When was Iambic Therapeutics' last funding round?

Iambic Therapeutics' most recent funding round was for $100M (USD) in October 2023.

How much has Iambic Therapeutics raised to-date?

As of Oct 3, 2023, Iambic Therapeutics has raised a total of $153M (USD).

How many employees does Iambic Therapeutics have?

Iambic Therapeutics has 75 employees as of Feb 5, 2024.

Iambic Therapeutics - Classification

Ownership
  • Private
Technology
  • AI
  • Machine Learning
  • Software
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
  • Government
Main Product
  • AI-driven Drug Discovery
  • Therapeutics Development
Tags
  • Biotech
  • Consulting
  • Drug Discovery
  • Healthtech
  • Rd
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software